Estrella Immunopharma Inc
NASDAQ:ESLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Estrella Immunopharma Inc
Revenue
Estrella Immunopharma Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Estrella Immunopharma Inc
NASDAQ:ESLA
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Revenue
$27.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
Schlumberger NV
NYSE:SLB
|
Revenue
$35.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
Halliburton Co
NYSE:HAL
|
Revenue
$22.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Revenue
$2.2B
|
CAGR 3-Years
56%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Revenue
$2.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Estrella Immunopharma Inc
Glance View
Estrella Immunopharma Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.
See Also
What is Estrella Immunopharma Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2025, Estrella Immunopharma Inc's Revenue amounts to 0 USD.
